Neonatal conjunctivitis caused by Chlamydia trachomatis

Area of Science:

• Neonatal infections
• Ophthalmology
• Pediatric infectious diseases

Background:

• Chlamydia trachomatis is a frequent cause of neonatal infections in industrialized nations.
• Infection is acquired from the maternal cervix, leading to colonization of mucosal surfaces like the conjunctiva, respiratory, and gastrointestinal tracts.
• Recognized manifestations include conjunctivitis and pneumonia, with C. trachomatis found in 14-25% of neonatal conjunctivitis cases.

Purpose of the Study:

• To outline the clinical manifestations and recommended treatment for Chlamydia trachomatis infections in neonates.
• To emphasize the importance of systemic therapy due to the potential for systemic spread.
• To provide guidance on appropriate antibiotic regimens for affected infants and their parents.

Main Methods:

• Review of clinical presentations and etiological agents of neonatal infections.
• Analysis of diagnostic findings for Chlamydia trachomatis in neonatal conjunctivitis and associated infections.
• Evaluation of established treatment protocols for neonatal chlamydial infections.

Main Results:

• Neonatal conjunctivitis, often the initial sign, can indicate systemic C. trachomatis infection.
• Oral erythromycin (25 mg/kg every 12 hours for 14 days) is the established treatment for neonatal chlamydial conjunctivitis.
• The recommended dosage of erythromycin is well-tolerated by infants.

Conclusions:

• Systemic therapy is crucial for neonatal Chlamydia trachomatis infections.
• Oral erythromycin is an effective and safe treatment for neonatal chlamydial conjunctivitis.
• Maternal and paternal treatment with oral erythromycin or tetracyclines is essential to prevent infant reinfection and transmission.